An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L
Clinical trial NCT06636552 · RECRUITING
Trial details
- NCT number
- NCT06636552
- Sponsor
- Hellenic Society of Hematology
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-19
- Primary completion
- 2029-01-05
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.